Elevance Health Reaffirms 2026 Earnings Guidance Despite Medicare Sanctions

summarizeSummary

Elevance Health reaffirmed its 2026 adjusted earnings and benefit expense ratio guidance, explicitly stating that the outlook includes the impact of recent CMS Medicare Advantage sanctions.

check_boxKey Events

• Reaffirms 2026 Earnings Guidance

  Elevance Health expects adjusted shareholders' earnings for full year 2026 to be at least $25.50 per diluted share.

• Benefit Expense Ratio Guidance Maintained

  The company also reaffirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.

• Guidance Includes CMS Sanctions Impact

  The reaffirmed guidance explicitly incorporates the financial impact of the Centers for Medicare & Medicaid Services (CMS) sanctions announced on March 2, 2026, which suspend new Medicare Advantage enrollments.

• GAAP Reconciliation Not Provided

  The company is currently unable to provide a reconciliation of its adjusted guidance to GAAP earnings due to the inability to reasonably estimate potential financial payments related to the CMS matter.

auto_awesomeAnalysis

This 8-K provides crucial clarity following the recent announcement of CMS sanctions on March 2, 2026. By reaffirming its full-year 2026 adjusted earnings guidance of at least $25.50 per diluted share and benefit expense ratio guidance, Elevance Health indicates that the financial impact of the Medicare Advantage enrollment suspension is already factored into its outlook. This communication aims to stabilize investor sentiment after a period of uncertainty, especially with the stock trading near its 52-week low. The inability to provide a GAAP reconciliation due to the unknown financial payments for the CMS matter highlights the ongoing complexity.